Literature DB >> 30334174

Lymph node dissection could bring survival benefits to patients diagnosed with clinically node-negative upper urinary tract urothelial cancer: a population-based, propensity score-matched study.

Fan Dong1, Tianyuan Xu2, Xianjin Wang1, Yifan Shen1, Xiaohua Zhang1, Shanwen Chen1, Shan Zhong3, Minguang Zhang4, Qiang Ding1.   

Abstract

OBJECTIVES: To evaluate the survival benefits that lymph node dissection (LND) brought to clinically node-negative upper tract urothelial carcinoma (UTUC) patients.
METHODS: Non-metastatic node-negative UTUC patients were identified from the Surveillance, Epidemiology and End Results database. N0 patients were naturally divided as cN0-pNx group (clinically diagnosed as N0 without LND performed) and cNx-pN0 group (pathologically diagnosed as node-negative no matter what clinical node status they have).
RESULTS: Of the 2731 patients included, 2240 and 491 cases were cN0-pNx and cNx-pN0, respectively. The overall survival (OS) of cNx-pN0 patients was significantly better than that of cNx-pN0 patients (p = 0.022). After propensity score matching, the survival of cNx-pN0 patients was still significantly better than cN0-pNx group. Besides, multivariate analyses showed cNx-pN0 (received LND) was an independent favorable prognostic factor for OS and CSS compared with cN0-pNx (no LND). Survival advantages of pN0 group were more significant in ≥ T2 patients and patients with tumor size ≤ 5 cm. Even in N0 patients who received adjuvant treatment, LND still brought obvious survival improvement (HRos = 0.565, p = 0.013; HRcss = 0.607, p = 0.046).
CONCLUSION: LND could improve survival outcomes in patients with clinically node-negative UTUC, especially for those with muscle-invasive diseases (T2-4 stages) or smaller tumor size (≤ 5 cm). Adjuvant treatment after nephroureterectomy is incapable of replacing the therapeutic role of LND.

Entities:  

Keywords:  Cancer-specific survival; Clinically node-negative; Lymph node dissection; Overall survival; Upper urinary tract urothelial cancer

Mesh:

Year:  2018        PMID: 30334174     DOI: 10.1007/s10147-018-1356-6

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  21 in total

1.  No overt influence of lymphadenectomy on cancer-specific survival in organ-confined versus locally advanced upper urinary tract urothelial carcinoma undergoing radical nephroureterectomy: a retrospective international, multi-institutional study.

Authors:  Maximilian Burger; Shahrokh F Shariat; Hans-Martin Fritsche; Juan Ignacio Martinez-Salamanca; Kazumasa Matsumoto; Thomas F Chromecki; Vincenzo Ficarra; Wassim Kassouf; Christian Seitz; Armin Pycha; Stefan Tritschler; Thomas J Walton; Giacomo Novara
Journal:  World J Urol       Date:  2011-06-01       Impact factor: 4.226

2.  The contemporary role of lymph node dissection during nephroureterectomy in the management of upper urinary tract urothelial carcinoma: the Canadian experience.

Authors:  Ross J Mason; Wassim Kassouf; David G Bell; Louis Lacombe; Anil Kapoor; Niels Jacobsen; Adrian Fairey; Jonathan Izawa; Peter Black; Simon Tanguay; Joseph Chin; Alan So; Jean-Baptiste Lattouf; Fred Saad; Edward Matsumoto; Darrel Drachenberg; Ilias Cagiannos; Yves Fradet; Ricardo A Rendon
Journal:  Urology       Date:  2012-02-25       Impact factor: 2.649

3.  Role of lymph node dissection in the treatment of urothelial carcinoma of the upper urinary tract: multi-institutional relapse analysis and immunohistochemical re-evaluation of negative lymph nodes.

Authors:  T Abe; N Shinohara; M Muranaka; A Sazawa; S Maruyama; T Osawa; T Harabayashi; K Kubota; Y Matsuno; T Shibata; Y Toyada; Y Shinno; K Minami; S Sakashita; A Kumagai; N Takada; M Togashi; H Sano; T Mori; K Nonomura
Journal:  Eur J Surg Oncol       Date:  2010-09-15       Impact factor: 4.424

Review 4.  The role of chemotherapy in the treatment of urothelial cell carcinoma of the upper urinary tract (UUT-UCC).

Authors:  François Audenet; David R Yates; Olivier Cussenot; Morgan Rouprêt
Journal:  Urol Oncol       Date:  2010-09-29       Impact factor: 3.498

5.  The impact of lymph node status and features on oncological outcomes in urothelial carcinoma of the upper urinary tract (UTUC) treated by nephroureterectomy.

Authors:  Adil Ouzzane; Pierre Colin; Tarek P Ghoneim; Marc Zerbib; Alexandre De La Taille; François Audenet; Fabien Saint; Nicolas Hoarau; Emilie Adam; Marie Dominique Azemar; Henri Bensadoun; Luc Cormier; Olivier Cussenot; Alain Houlgatte; Gilles Karsenty; Charlotte Maurin; François Xavier Nouhaud; Véronique Phe; Thomas Polguer; Mathieu Roumiguié; Alain Ruffion; Morgan Rouprêt
Journal:  World J Urol       Date:  2012-12-11       Impact factor: 4.226

6.  Prognostic value of lymph node dissection in patients with muscle-invasive transitional cell carcinoma of the upper urinary tract.

Authors:  Marco Roscigno; Cesare Cozzarini; Roberto Bertini; Vincenzo Scattoni; Massimo Freschi; Luigi Filippo Da Pozzo; Alberto Briganti; Andrea Gallina; Umberto Capitanio; Renzo Colombo; Guazzoni Giorgio; Francesco Montorsi; Patrizio Rigatti
Journal:  Eur Urol       Date:  2008-01-15       Impact factor: 20.096

7.  A critical appraisal of the value of lymph node dissection at nephroureterectomy for upper tract urothelial carcinoma.

Authors:  Giovanni Lughezzani; Claudio Jeldres; Hendrik Isbarn; Shahrokh F Shariat; Maxine Sun; Daniel Pharand; Hugues Widmer; Philippe Arjane; Markus Graefen; Francesco Montorsi; Paul Perrotte; Pierre I Karakiewicz
Journal:  Urology       Date:  2009-10-28       Impact factor: 2.649

8.  Impact of lymph node dissection on cancer specific survival in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy.

Authors:  Marco Roscigno; Shahrokh F Shariat; Vitaly Margulis; Pierre Karakiewicz; Mesut Remzi; Eiji Kikuchi; Cord Langner; Yair Lotan; Alon Weizer; Karim Bensalah; Jay D Raman; Christian Bolenz; Charles C Guo; Christopher G Wood; Richard Zigeuner; Jeffrey Wheat; Wareef Kabbani; Theresa M Koppie; Casey K Ng; Nazareno Suardi; Roberto Bertini; Mario I Fernández; Shuji Mikami; Masaru Isida; Maurice Stephan Michel; Francesco Montorsi
Journal:  J Urol       Date:  2009-04-16       Impact factor: 7.450

9.  Prospective clinical trial of the feasibility and safety of modified retroperitoneal lymph node dissection at time of nephroureterectomy for upper tract urothelial carcinoma.

Authors:  Sandhya R Rao; Jose J Correa; Wade J Sexton; Julio M Pow-Sang; Shohreh I Dickinson; Hui-Yi Lin; Philippe E Spiess
Journal:  BJU Int       Date:  2012-05-04       Impact factor: 5.588

10.  The extent of lymphadenectomy seems to be associated with better survival in patients with nonmetastatic upper-tract urothelial carcinoma: how many lymph nodes should be removed?

Authors:  Marco Roscigno; Shahrokh F Shariat; Vitaly Margulis; Pierre Karakiewicz; Mesut Remzi; Eiji Kikuchi; Richard Zigeuner; Alon Weizer; Arthur Sagalowsky; Karim Bensalah; Jay D Raman; Christian Bolenz; Wassim Kassou; Theresa M Koppie; Christopher G Wood; Jeffrey Wheat; Cord Langner; Casey K Ng; Umberto Capitanio; Roberto Bertini; Mario I Fernández; Shuji Mikami; Masaru Isida; Philipp Ströbel; Francesco Montorsi
Journal:  Eur Urol       Date:  2009-06-18       Impact factor: 20.096

View more
  7 in total

Review 1.  Robotic nephroureterectomy in the management of upper tract urothelial cancer: inching toward standard of care?

Authors:  Sumit Saini; Ram Anil Pathak; Ashok Kumar Hemal
Journal:  Int Urol Nephrol       Date:  2022-05-24       Impact factor: 2.266

2.  Is Lymph Node Dissection Necessary During Radical Nephroureterectomy for Clinically Node-Negative Upper Tract Urothelial Carcinoma? A Multi-Institutional Study.

Authors:  Hsiang-Ying Lee; Chao-Hsiang Chang; Chi-Ping Huang; Chih-Chin Yu; Chi-Wen Lo; Shiu-Dong Chung; Wei-Che Wu; I-Hsuan Alan Chen; Jen-Tai Lin; Yuan-Hong Jiang; Yu-Khun Lee; Thomas Y Hsueh; Allen W Chiu; Yung-Tai Chen; Chang-Min Lin; Yao-Chou Tsai; Wei-Chieh Chen; Bing-Juin Chiang; Hsu-Che Huang; Chung-Hsin Chen; Chao-Yuan Huang; Chia-Chang Wu; Wei Yu Lin; Jen-Shu Tseng; Hung-Lung Ke; Hsin-Chih Yeh
Journal:  Front Oncol       Date:  2022-04-29       Impact factor: 5.738

3.  Clinical Efficacy of Adjuvant Chemotherapy in Advanced Upper Tract Urothelial Carcinoma (pT3-T4): Real-World Data from the Taiwan Upper Tract Urothelial Carcinoma Collaboration Group.

Authors:  Chung-Yu Lin; Han-Yu Weng; Ta-Yao Tai; Hsi-Chin Wu; Wen-Chi Chen; Chung-Hsin Chen; Chao-Yuan Huang; Chi-Wen Lo; Chih-Chin Yu; Chung-You Tsai; Wei-Che Wu; Yuan-Hong Jiang; Yu-Khun Lee; Thomas Y Hsueh; Allen W Chiu; Bing-Juin Chiang; Hsu-Che Huang; I-Hsuan Alan Chen; Yung-Tai Chen; Wei-Yu Lin; Chia-Chang Wu; Yao-Chou Tsai; Hsiang-Ying Lee; Wei-Ming Li
Journal:  J Pers Med       Date:  2022-02-06

Review 4.  Lymph Node Dissection During Radical Nephro-Ureterectomy for Upper Tract Urothelial Carcinoma: A Review.

Authors:  Arthur Peyrottes; Gianluigi Califano; Idir Ouzaïd; Paul Lainé-Caroff; Thibaut Long Depaquit; Jean-François Hermieu; Evanguelos Xylinas
Journal:  Front Surg       Date:  2022-03-24

Review 5.  MicroRNA Signatures in the Upper Urinary Tract Urothelial Carcinoma Scenario: Ready for the Game Changer?

Authors:  Alessandra Cinque; Anna Capasso; Riccardo Vago; Matteo Floris; Michael W Lee; Roberto Minnei; Francesco Trevisani
Journal:  Int J Mol Sci       Date:  2022-02-26       Impact factor: 5.923

Review 6.  Prognostic Value of Tumor Size in Patients with Upper Tract Urothelial Carcinoma: A Systematic Review and Meta-analysis.

Authors:  Runzhuo Ma; Zenan Liu; Yinchu Cheng; Pengxiang Zhou; Yuting Pan; Hai Bi; Liyuan Tao; Bin Yang; Haizhui Xia; Xuehua Zhu; Jide He; Wei He; Guoliang Wang; Yi Huang; Lulin Ma; Jian Lu
Journal:  Eur Urol Open Sci       Date:  2022-06-28

7.  Effect of lymph node dissection on stage-specific survival in patients with upper urinary tract urothelial carcinoma treated with nephroureterectomy.

Authors:  Ting-Shuai Zhai; Liang Jin; Zhen Zhou; Xiang Liu; Huan Liu; Wei Chen; Jing-Yi Lu; Xu-Dong Yao; Li-Ming Feng; Lin Ye
Journal:  BMC Cancer       Date:  2019-12-12       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.